BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31866498)

  • 1. Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients.
    Carpagnano GE; Scioscia G; Lacedonia D; Stornelli SR; Irene Quarato CM; Soccio P; Resta O; Foschino Barbaro MP
    Pulm Pharmacol Ther; 2020 Feb; 60():101879. PubMed ID: 31866498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
    Crisafulli E; Zanini A; Pisi G; Pignatti P; Poli G; Scuri M; Chetta A
    Expert Rev Respir Med; 2016; 10(5):481-90. PubMed ID: 26938578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
    Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I
    Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
    Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
    Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
    Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
    BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status.
    Brusselle G; Peché R; Van den Brande P; Verhulst A; Hollanders W; Bruhwyler J
    Respir Med; 2012 Jun; 106(6):811-9. PubMed ID: 22357130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of extrafine beclomethasone dipropionate/formoterol fumarate dry powder inhaler and pressurized metered-dose inhaler in Chinese patients with asthma: the FORTUNE study.
    Zheng J; Zhang J; Fu X; Lin C; Zhang X; Mei X; Corradi M; Cappellini G; Calabro E; Zhu C; Topole E
    J Asthma; 2024 Apr; 61(4):360-367. PubMed ID: 37878325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment response according to small airway phenotypes: a real-life observational study.
    Marth K; Spinola M; Kisiel J; Woergetter C; Petrovic M; Pohl W
    Ther Adv Respir Dis; 2016 Jun; 10(3):200-10. PubMed ID: 27060186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.
    O'Connor BJ; Collarini S; Poli G; Brindicci C; Spinola M; Acerbi D; Barnes PJ; Leaker B
    BMC Pulm Med; 2011 Dec; 11():60. PubMed ID: 22188731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler.
    Singh D; van den Berg F; Leaker B; Corradi M; Jabbal S; Collarini S; Mongelli V; Santoro L; Piccinno A; Biondaro S; Lipworth B
    Br J Clin Pharmacol; 2019 Apr; 85(4):729-736. PubMed ID: 30586199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both bronchial and alveolar exhaled nitric oxide are reduced with extrafine beclomethasone dipropionate in asthma.
    Nicolini G; Chetta A; Simonazzi A; Tzani P; Aiello M; Olivieri D
    Allergy Asthma Proc; 2010; 31(5):85-90. PubMed ID: 20929599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
    Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
    Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
    Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of extrafine formulation of BDP/FF inhaler on asthma control, small airway function and airway inflammation among Mexican asthmatic patients. A retrospective analysis.
    Díaz-García R; Flores-Ramírez G; Ramírez-Oseguera RT
    Respir Med; 2020; 165():105932. PubMed ID: 32308205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy - CONTROL study.
    Dębowski T; Marko M; Rogala B; Majak P; Pawliczak R
    Pulm Pharmacol Ther; 2024 Mar; 84():102272. PubMed ID: 38036258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
    Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
    NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study.
    Pohunek P; Varoli G; Reznichenko Y; Mokia-Serbina S; Brzostek J; Kostromina V; Kaladze M; Muraro A; Carzana E; Armani S; Kaczmarek J
    Eur J Pediatr; 2021 May; 180(5):1467-1475. PubMed ID: 33404895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrafine HFA-beclomethasone-formoterol vs. nonextrafine combination of an inhaled corticosteroid and a long acting β2-agonist in patients with persistent asthma: A systematic review and meta-analysis.
    Liu T; Yang D; Liu C
    PLoS One; 2021; 16(9):e0257075. PubMed ID: 34478483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.